Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RPS6KB1 | P23443 | 7/20 | 0.55 |
| ▸ | AKT1 | P31749 | 11/20 | 0.42 |
| ▸ | AKT2 | P31751 | 8/20 | 0.42 |
| ▸ | RPS6KA3 | P51812 | 3/20 | 0.42 |
| ▸ | GSK3B | P49841 | 1/20 | 0.42 |
| ▸ | ROCK2 | O75116 | 4/20 | 0.37 |
| ▸ | AKT3 | Q9Y243 | 3/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | AKT1S1 | Q96B36 | 3/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL473365 | 0.92 | RPS6KB1 (0.46) | RPS6KB1AKT1AKT2RPS6KA3GSK3B | |
| SCHEMBL10157823 | 0.89 | AKT2 (0.42) | RPS6KB1AKT1AKT2GSK3BROCK2 | |
| SCHEMBL473355 | 0.88 | AKT1 (0.43) | RPS6KB1AKT1AKT2RPS6KA3GSK3B | |
| SCHEMBL25083523 | 0.87 | RPS6KB1 (0.55) | RPS6KB1AKT1AKT2RPS6KA3GSK3B | |
| SCHEMBL473379 | 0.84 | RPS6KB1 (0.53) | RPS6KB1AKT1AKT2RPS6KA3GSK3B | |
| SCHEMBL473380 | 0.84 | RPS6KB1 (0.53) | RPS6KB1AKT1AKT2RPS6KA3GSK3B | |
| SCHEMBL473322 | 0.84 | AKT1 (0.42) | RPS6KB1AKT1AKT2RPS6KA3GSK3B | |
| SCHEMBL473338 | 0.84 | RPS6KB1 (0.53) | RPS6KB1AKT1AKT2RPS6KA3GSK3B | |
| SCHEMBL29894639 | 0.84 | RPS6KB1 (0.53) | RPS6KB1AKT1AKT2RPS6KA3GSK3B | |
| SCHEMBL23532535 | 0.84 | AKT2 (0.44) | RPS6KB1AKT1AKT2RPS6KA3GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230064189-A1 | 1H-PYRAZOLO[3,4-D]PYRIMIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF PLATINUM-RESISTANT CANCER | IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) | 2023-03-02 | — | — | US | claimed |
| US-20230064189-A1 | 1H-PYRAZOLO[3,4-D]PYRIMIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF PLATINUM-RESISTANT CANCER | IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) | 2023-03-02 | — | — | US | disclosed |
| US-20230064189-A1 | 1H-PYRAZOLO[3,4-D]PYRIMIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF PLATINUM-RESISTANT CANCER | IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) | 2023-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230064189-A1 | 1H-PYRAZOLO[3,4-D]PYRIMIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF PLATINUM-RESISTANT CANCER | DPYD, ABCC1, TYMP | RPS6KB1 1491/4885AKT1 2327/4885AKT2 2208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.